You can buy or sell PTN and other stocks, options, ETFs, and crypto commission-free!
Palatin Technologies, Inc., also called Palatin Technologies, is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). Read More The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Cranbury, New Jersey
52 Week High
52 Week Low
Stock Price, News, & Analysis for Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, ...
Yahoo FinanceFeb 26
Analysis: Positioning to Benefit within Weatherford International, NiSource, Palatin Technologies, Astronics, MaxLinear, and FutureFuel — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Weatherford International PLC (WFT), NiSource, Inc (NI), Palatin Technologies, Inc. (PTN), Astronics Corporation (ATRO), MaxLinear, Inc (MXL), and FutureFuel Corp. (FF), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. C...
Expected May 15, Pre-Market